Skip to main content
. 2023 May;39(3):361–390. doi: 10.6515/ACS.202305_39(3).20230301A

Figure 3.

Figure 3

Comparison of different rapid sequencing strategies of foundational therapies. (A) Seven different sequencing strategies. (B) The best sequence for reducing the composite of heart failure hospitalization and cardiovascular death was the accelerated sequence of SGLT2i/MRA/ARNI/beta-blocker within 12 weeks. (C) Six different sequencing strategies starting with combination therapy. (D) The best sequencing for reducing the composite endpoints was the sequence starting with the combination of SGLT2i plus MRA, followed by an ARNI and then beta-blocker. * ARNI can be prescribed when systolic blood pressure ≥ 100 mmHg. ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blocker; CV, cardiovascular; HHF, heart failure hospitalization; MRA, mineralcorticoidreceptor antagonist; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose co-transporter 2 inhibitor.